When stratified by comparator groups, the pooled estimate was most favorable in monotherapy trials versus placebo (SMD 2.41, 95% CI 4.43 to 0.39), whereas the add-on designs versus the same background treatment (SMD 0.65, 95% CI 1.85 to 0.55), head-to-head comparisons versus another drug (SMD 0.19, 95% CI 0.84 to 0.45), and add-on designs versus placebo (SMD 0.65, 95% CI 1.35 to 0.06) showed more modest estimates and did not provide clear evidence of a between-group difference overall (p=0.21)
Organ Growth Concerns at High Doses Because IGF-1 acts on all tissue not just muscle megadosing for extended periods may promote organ tissue hypertrophy, including intestinal walls and heart tissue
Regular use may provide noticeable improvements in skin tone and complexion, while contributing to the bodys natural glutathione levels
The "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk" provides clear recommendations for estimating cardiovascular disease risk
Statements Author contributions SC participated in experimental studies
